These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35158141)

  • 21. Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant.
    Piñana JL; Serra MÁ; Hernández-Boluda JC; Navarro D; Calabuig M; Solano C
    Transpl Infect Dis; 2016 Feb; 18(1):89-92. PubMed ID: 26485423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
    Asselah T; Marcellin P
    Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.
    Langness JA; Tabano D; Wieland A; Tise S; Pratt L; Harrington LA; Lin S; Ghuschcyan V; Nair KV; Everson GT
    Ann Hepatol; 2017; 16(3):366-374. PubMed ID: 28425406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium.
    Degré D; Sersté T; Lasser L; Delwaide J; Starkel P; Laleman W; Langlet P; Reynaert H; Bourgeois S; Vanwolleghem T; Negrin Dastis S; Gustot T; Geerts A; Van Steenkiste C; de Galocsy C; Lepida A; Orlent H; Moreno C
    PLoS One; 2017; 12(1):e0170933. PubMed ID: 28125694
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.
    Gimeno-Ballester V; Simón MÁ; Trigo C; Mar J; San Miguel R
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1289-1303. PubMed ID: 27626505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection.
    Sulkowski MS; Vargas HE; Di Bisceglie AM; Kuo A; Reddy KR; Lim JK; Morelli G; Darling JM; Feld JJ; Brown RS; Frazier LM; Stewart TG; Fried MW; Nelson DR; Jacobson IM;
    Gastroenterology; 2016 Feb; 150(2):419-29. PubMed ID: 26497081
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort.
    Sanchez Antolin G; Testillano M; Pascasio JM; Narvaez Rodriguez I; Prieto M; Otero A; Herrero JI; Londoño M; Fernandez Vazquez I; Castells L;
    Transplant Proc; 2016 Nov; 48(9):3013-3016. PubMed ID: 27932134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study.
    Kwo P; Gitlin N; Nahass R; Bernstein D; Etzkorn K; Rojter S; Schiff E; Davis M; Ruane P; Younes Z; Kalmeijer R; Sinha R; Peeters M; Lenz O; Fevery B; De La Rosa G; Scott J; Witek J
    Hepatology; 2016 Aug; 64(2):370-80. PubMed ID: 26799692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience.
    El-Khayat HR; Fouad YM; Maher M; El-Amin H; Muhammed H
    Gut; 2017 Nov; 66(11):2008-2012. PubMed ID: 27511197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
    Gayam V; Tiongson B; Khalid M; Mandal AK; Mukhtar O; Gill A; Garlapati P; Shrestha B; Khalid M; Chakraborty S; Guss D; Sherigar J; Mansour M; Mohanty S
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1200-1207. PubMed ID: 30096090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Interferon-free therapy for Hepatitis C in Germany--an application of the efficiency frontier approach.
    Gissel C; Götz G; Mahlich J; Repp H
    BMC Infect Dis; 2015 Jul; 15():297. PubMed ID: 26223310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir.
    Collins JM; Raphael KL; Terry C; Cartwright EJ; Pillai A; Anania FA; Farley MM
    Clin Infect Dis; 2015 Oct; 61(8):1304-6. PubMed ID: 26082511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the genetic toxicity of sofosbuvir and simeprevir with and without ribavirin in a human-derived liver cell line.
    Librelotto CS; Souza AP; Álvares-DA-Silva MR; Simon D; Dihl RR
    An Acad Bras Cienc; 2021; 93(4):e20200632. PubMed ID: 34586319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
    New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in HCV genotype IV infected patients.
    Wang BQ; Wang YL; Shi KQ
    Liver Int; 2017 May; 37(5):765. PubMed ID: 27753263
    [No Abstract]   [Full Text] [Related]  

  • 37. Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
    Hézode C; Fourati S; Chevaliez S; Scoazec G; Soulier A; Varaut A; François M; Ruiz I; Roudot-Thoraval F; Mallat A; Pawlotsky JM
    Clin Infect Dis; 2017 Jun; 64(11):1615-1618. PubMed ID: 28369411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to Real life Egyptian experience of efficacy / safety of Simeprevir\ Sofosbuvir in HCV genotype IV.
    Eletreby R; Elakel W; El Raziky M; Esmat G
    Liver Int; 2017 May; 37(5):766. PubMed ID: 28453921
    [No Abstract]   [Full Text] [Related]  

  • 39. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.
    Pillai AA; Wedd J; Norvell JP; Parekh S; Cheng N; Young N; Spivey JR; Ford R
    Am J Gastroenterol; 2016 Feb; 111(2):250-60. PubMed ID: 26832650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.